MSRA-5

1. MSRA-5 has no effect on falls in humans (aRR 0.99 (0.95-1.02)).

   “Compared to those negative in MSRA-5, adjusted relative risk is similar for falls (0.99 (0.95-1.02)), ED (1.04 (0.99-1.11)) and hospital admission (1.06 (0.99-1.15)).”

   Humanscommunity-dwelling adults3 yearsn = 230

   Validating the Mini Sarcopenia Risk Assessment (MSRA) in Sarcopenia Case-finding for Healthy Older Adults

   GSA 2025 abstract·31 Dec 2025

1. MSRA-5 has no effect on falls, ED or hospital admission in humans (aOR 1.03 (0.98 – 1.09)).

   “Adjusted odds ratio for composite outcome of ≥ 1 falls, ED or hospital admission was 1.03 (0.98 – 1.09).”

   Humanscommunity-dwelling adults3 yearsn = 230

   Validating the Mini Sarcopenia Risk Assessment (MSRA) in Sarcopenia Case-finding for Healthy Older Adults

   GSA 2025 abstract·31 Dec 2025

1. MSRA-5 has no effect on Frenchay Activities Index in humans (β = -0.02 (-0.08 – 0.04)).

   “Adjusted, there was no significant association between MSRA-5 and FAI (β = -0.02 (-0.08 – 0.04)), IPAQ (β = -2.85 (-47.91 – 42.20)), LSA (β = 0.02 (-0.27 – 0.30)), or EQ5D (β = 0.08 (-0.12– 0.28)).”

   Humanscommunity-dwelling adults3 yearsn = 230

   Validating the Mini Sarcopenia Risk Assessment (MSRA) in Sarcopenia Case-finding for Healthy Older Adults

   GSA 2025 abstract·31 Dec 2025

More on Frenchay Activities Index